Commentary

Protease Inhibitors: The Good and the Bad

Published in AIDS Weekly, August 19th, 1996

There is still no cure for AIDS.

It says so right there in the patient-information section of the package inserts for the three U.S.- approved protease inhibitors: saquinavir (Hoffman-LaRoche's Invirase), indinavir (Merck's Crixivan), and ritonavir (Abbott's Norvir).

This remains true despite the widely held belief that people with HIV infection can indefinitely postpone disease by adding an HIV protease inhibitor to their treatment regimens.

There is solid evidence in support of this idea: as many as 90 percent of clinical-trial participants who receive a protease inhibitor plus zidovudine (AZT) plus lamivudine (3TC) have had...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-08-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry